Safety profile and medium- to long-term protection of the Recombinant Zoster Vaccine (RZV) in a cohort of high-risk patients: real-world data from a General Hospital in Southern Italy, 2021–2025
The study demonstrates RZV safety and HZ protection in vulnerable patients, consistently with available evidence.
Authors
- Andrea Martinelli (ORCID: https://orcid.org/0000-0002-8068-6246)
- Pasquale Stefanizzi (ORCID: https://orcid.org/0000-0002-3279-0196)
- Giuseppe Spinelli (ORCID: https://orcid.org/0000-0003-3834-0433)
- Antonio Di Lorenzo (ORCID: https://orcid.org/0000-0002-2879-3001)
- Silvio Tafuri (ORCID: https://orcid.org/0000-0003-4194-0210)
- Lorenza Moscara (ORCID: https://orcid.org/0000-0002-4691-1614)
- Chiara Scaltrito
- Claudia Palmieri (ORCID: https://orcid.org/0009-0009-1295-4251)
- Francesca Oliveto
- Petra Buonvino
- Giovanna Pice
- Laura Marchisella
Institutions
- Altera (United States) (US)
- Polyclinic General Hospital (GR)
- University of Bari Aldo Moro (IT)
Publication Details
- Journal
- Expert Review of Vaccines
- Published
- 2025-11-12
- DOI
- https://doi.org/10.1080/14760584.2025.2589216
- Citations
- 2
- Primary Topic
- Herpesvirus Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.71